OTEMTO

March 31, 2016May 13, 2016

Stiolto Respimat for COPD Granted FDA’s Supplemental NDA Approval

Chronic Bronchitis, COPD, Emphysema, News

The FDA has approved a supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s Stiolto Respimat, which, according to the company, adds data to the product’s label demonstrating improvements in health and quality ... Read more

October 28, 2015November 9, 2015

Boehringer’s STIOLTO RESPIMAT Shows Promising Results Clinical Trials

COPD, News

Post-hoc analysis of the TONADO and OTEMTO trials of the 15,000-patient phase III Chronic Obstructive Pulmonary Disease (COPD) clinical trial TOviTO assessing Boehringer Ingelheim‘s STIOLTO RESPIMAT’s efficacy and safety in COPD were recently ... Read more

September 29, 2015November 9, 2015

New Data Reveals Spiolto Respimat Improves Management of COPD Patients’ Symptoms

COPD, News

Boehringer Ingelheim recently published new findings from two recent trials, the OTEMTO® 1&2 study and the ENERGITO® study, both of which showed that people with chronic obstructive pulmonary disease (COPD) had an ... Read more

August 18, 2015November 9, 2015

Boehringer Ingelheim’s Spiolto Respimat Improves Quality of Life in COPD Patients

COPD, News

Boehringer Ingelheim recently announced new positive data on the Phase IIIb OTEMTO® 1 and 2 trials (NCT01964352 and NCT02006732) on Spiolto® Respimat® (tiotropium plus olodaterol) in patients with chronic obstructive ... Read more